1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody comprising a heavy chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 7, 8, and 9, respectively, wherein the monoclonal antibody specifically binds *Staphylococcus aureus* protein A (SpA) with a K_D of less than 1×10^{-10} M via its Fab region paratope, wherein the monoclonal antibody is able to displace human IgG immunoglobulins bound to SpA on *Staphylococcus aureus* bacteria via their Fc regions.

2. The pharmaceutical composition of claim 1, wherein the monoclonal antibody is able to mediate opsonization of SpA-expressing *Staphylococcus aureus* bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.

3. The pharmaceutical composition of claim 1, wherein the monoclonal antibody is a human or humanized IgG3 monoclonal antibody.

4. The pharmaceutical composition of claim 1, wherein the monoclonal antibody specifically binds to the amino acid sequence SEQ ID NO: 1.

5. The pharmaceutical composition of claim 1, wherein the heavy chain variable domain comprises SEQ ID NO: 5 and the light chain variable domain comprises SEQ ID NO: 10.

6. The pharmaceutical composition of claim 5, wherein the monoclonal antibody is able to mediate opsonization of SpA-expressing *Staphylococcus aureus* bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.

7. The pharmaceutical composition of claim 5, wherein the monoclonal antibody is a human or humanized IgG3 monoclonal antibody.

8. The pharmaceutical composition of claim 5, wherein the monoclonal antibody specifically binds to the amino acid sequence SEQ ID NO: 1.